8 / 30
Page 47
Notes:
December 03-04, 2018 | Chicago, USA
American Pathology and Oncology Research
&
15
th
International Congress on
Microbial Genetics and Molecular Microbiology
International Conference on
Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8
Evaluation of the antitumoral effects and mechanisms of action of novel binuclear Cu-complexes on
tumorigenesis
Zeinab Ghasemishahrestani
Federal University of Rio de Janeiro, Brazil
C
ancer is one of the major causes of death across the world. Hence, the development of chemotherapeutic strategies involving
novel antitumor agents has been the focus area of cancer treatment. The anticancer activities of copper complexes have
been the focus of much research to discover novel anticancer agents. Current study deals with the effects of two novel binuclear
copper (II) complexes with N
2
O-doner tridentate ligands (R9 and R10) on cytotoxic effects on the breast (MCF-7), lung (A549)
and prostate (PC3) cancer cell lines. MCF-7, A549, and PC3 cell lines were analyzed using MTT assay and Flow Cytometry
intracellular ROS production assay. MCF-7, A549, and PC3 treated with R9 showed an IC50 of 1.282±0.14, 1.428±0.07 and
1.60±0.08, respectively. On the other hand, MCF-7, A549 and PC3 cell lines affected by R10 exhibited (IC
50
=1.006±0.18,
IC
50
=1.138±0.22, IC
50
=1.44±0.12, respectively). Flow cytometry assay for MCF-7 and A549 at three different concentrations
0.5, 1 and 2μM illustrated that cells tested with R9 and R10 presented ROS accumulation in a dose-dependent manner. In the
case of testing, some of R9 and R10 concentration, the increase of ROS production was even higher than the positive control,
doxorubicin. Cytotoxicity and induction of high amount of ROS may be considered R9 and R10 a potential therapeutic agent
for breast, lung and prostate cancer. We will further work on these compounds to understand the exact mechanism of action
of these novel complexes to pursue our investigation on their effects
in vitro
and
in vivo.
Biography
Zeinab Ghasemishahrestani has completed her MSc in Biochemistry from Pune University in India with O grade and she is doing the PhD in UFRJ in Brazil
regarding cancer research under the guidance of professors Marcos Dias Pereira and Andre Luis Souza dos Santos. She is publishing 5 papers in reputed journals.
farzaneh.ghasemi.sha@gmail.comZeinab Ghasemishahrestani, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C5-058